GIANT BIOGENE (02367) cancels 9.2 million repurchased shares.
Giant Group Bio (02367) announced that on April 20, 2026, the company cancelled 9.2 million shares of repurchased stock.
GIANT BIOGENE (02367) announces that on April 20, 2026, the company cancelled 9.2 million repurchased shares.
Related Articles
LUYE PHARMA's innovative drug LY03015 (VMAT2 inhibitor/Sigma-1R agonist) completed the first subject enrollment in its US PK bridging clinical trial.
J&T EXPRESS-W (01519) spent 15.617 million Hong Kong dollars on repurchasing 1.49 million shares on April 20th.
On April 20th, DMALL (02586) spent 5.2226 million Hong Kong dollars to repurchase 713,600 shares.
LUYE PHARMA's innovative drug LY03015 (VMAT2 inhibitor/Sigma-1R agonist) completed the first subject enrollment in its US PK bridging clinical trial.
J&T EXPRESS-W (01519) spent 15.617 million Hong Kong dollars on repurchasing 1.49 million shares on April 20th.
On April 20th, DMALL (02586) spent 5.2226 million Hong Kong dollars to repurchase 713,600 shares.
RECOMMEND
Hong Kong Hard‑Tech Companies Enhance Canton Fair Presence As Veterans And Newcomers Expand International Networks
17/04/2026
Thousand‑Fold Oversubscription In Hong Kong IPOs Signals Multiple Market Shifts
17/04/2026
Rising Compute Costs Drive Industry Price Increases As Institutions Expect Internet Firms To Outperform In Q1
17/04/2026
